# A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS

> **NCT02473627** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DS-1971a
- **DRUG:** midazolam hydrochloride
- **DRUG:** Omeprazole
- **DRUG:** Pioglitazone hydrochloride
- **DRUG:** Buproprion
- **DRUG:** Tolbutamide

## Key facts

- **NCT ID:** NCT02473627
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473627, "A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02473627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*